|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combination of long noncoding RNA <i>MALAT1</i> and carcinoembryonic antigen for the diagnosis of malignant pleural effusion caused by lung cancer.
|
29731641 |
2018 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, NCA constitutes most of the "CEA-like" immunoreactivity previously described in lung cancers.
|
1330929 |
1992 |
|
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The levels of CEA and CA125 in IPF patients were much higher in IPF patients with lung cancer (P ≤ .001).
|
29094803 |
2018 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Numerous potential DNA biomarkers such as hypermethylations of the promoters and mutations in K-ras, p53, and protein biomarkers; carcinoembryonic antigen (CEA), CYFRA21-1, plasma kallikrein B1 (KLKB1), Neuron-specific enolase, etc. have been discovered as lung cancer biomarkers.
|
18823584 |
2008 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum levels of SCC, Cyfra21-1, and CEA are markedly increased with increasing urinary albumin excretion, which affects the specificity for diagnosis for lung cancer.
|
28744310 |
2017 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results indicated that history of chronic obstructive pulmonary disease (OR = 2.59, 95% CI: 1.09, 6.15; P = 0.03), adenocarcinoma (OR = 2.28, 95% CI: 1.88, 2.77; P < 0.01), advanced tumour stage (TNM III-IV vs. I-II, OR = 2.38, 95% CI: 1.99, 2.86; P < 0.01), history of central venous catheter (OR = 1.95, 95% CI: 1.36, 2.78; P < 0.01), history of chemotherapy (OR = 2.32, 95% CI: 1.80, 2.99, P < 0.01), high levels of D-dimer (WMD = 4.31, 95% CI: 2.53, 6.10; P < 0.01) and carcinoembryonic antigen (WMD = 10.30, 95% CI: 9.95, 10.64; P < 0.01) and a low level of partial pressure of oxygen (WMD = -25.97, 95% CI: -31.31, -20.62; P < 0.01) were clinical features of LC patients with PE compared to those without PE.
|
31568496 |
2019 |
|
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the recovery of carcinoembryonic antigen to pre-radiation levels was more rapid in lung cancer patients with high levels of HIF-2α expression, and these patients had shorter survival times (P = 0.018).
|
26782458 |
2015 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The authors built a model for lung cancer diagnosis previously based on the blood biomarkers progastrin-releasing peptide (ProGRP), carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC), and cytokeratin 19 fragment (CYFRA21-1).
|
28940455 |
2018 |
|
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, patients with lung fibrosis, pancreatic cancer, uremia, chronic obstructive pulmonary disease, colon cancer, Alzheimer's disease, rectum cancer, and lung cancer had highest media levels of serum CEA in a descending order.
|
30905451 |
2019 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined use of salivary biomarkers and carcinoembryonic antigen for lung cancer detection in a Chinese population.
|
31374012 |
2019 |
|
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Association of neurologic manifestations and CEA levels with the diagnosis of brain metastases in lung cancer patients.
|
30903516 |
2019 |
|
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
For the diagnosis of malignant pleural effusion caused by lung cancer, LUNX mRNA exhibited higher sensitivity (80%), when compared with vascular endothelial growth factor mRNA (65%), carcinoembryonic antigen (67%) and Cyfra21-1 (61%), with the same specificity (95%).
|
25425729 |
2014 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diagnostic value of pleural interleukin 17 and carcinoembryonic antigen in lung cancer patients with malignant pleural effusions.
|
24072496 |
2014 |
|
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These findings suggest that NCA is a major member of the CEA-related gene family expressed in lung cancer.
|
7678982 |
1993 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multivariate logistic regression model (LRM) identified tumor size, CEA, SCC, CYFRA21-1, pro-GRP, and HE4 as independent risk factors for lung cancer.
|
29412152 |
2018 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, the new panel performed significantly better in lung cancer screening than did CEA and CA125 in all of the cohorts (<i>p</i>< .05).
|
31646071 |
2019 |
|
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Serum CEA levels were quantified in each patient at the time of diagnosis of lung cancer.
|
31410309 |
2019 |
|
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Detecting CTCs and tumor cells in BALF had similar areas under curves (AUC =0.871 and 0.963, respectively; P>0.05) in discriminating benign lesions from lung cancer (sensitivity 83.8% and 92.6%, specificity 86.5% and 99.9%, respectively), both of which were larger than those of NSE, CEA, and CA125 (AUC =0.564, 0.512 and 0.554, respectively; all P<0.05).
|
29780629 |
2018 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compared with the traditional lung cancer diagnostic biomarkers carcinoembryonic antigen and cytokeratin 19 fragment, GpAEA and sphingosine were as good or more appropriate for detecting lung cancer.
|
25961003 |
2015 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
About 37.5% of carcinoembryonic antigen (CEA)-negative lung cancer patients were CR-1 positive at 95% specificity.
|
26605871 |
2017 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
A classification rule based on EGF, sCD26, Calprotectin and CEA was established, able to reasonably discriminate lung cancer with 97% sensitivity and 43% specificity in the training set, and 91.7% sensitivity and 45.4% specificity in the validation set.
|
28117344 |
2017 |
|
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Two tests in lung cancer (ERCC1 and EGFR) and 1 test in breast cancer (CEA/CA15-3/CA27.29) were identified as top research priorities.
|
22274803 |
2012 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phospholipases release CEA from tumor cells resulting in high circulating serum levels of soluble CEA (sCEA) that has been validated as marker for progression of colorectal, breast, and lung cancers. sCEA also acts as a competitive inhibitor for anticancer strategies targeting membrane-bound CEA.
|
19342971 |
2009 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we analyzed the serum levels of six tumor markers (CEA, CYFRA21-1, SCC, NSE, ProGRP, and CA125) in 2097 suspected patients with lung cancer and determined whether the combination of the tumor markers was useful for histological diagnosis of lung cancer.
|
28607926 |
2017 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The significance of combined serum CEA and CA125 detection in lung cancer is confirmed.
|
30672447 |
2018 |